A5103255631- Opioid Use Disorder Treatment
- Substance Abuse Treatment and Outcomes
- Treatment of Major Depression
- Schizophrenia research and treatment
- Pain Management and Opioid Use
- Neurotransmitter Receptor Influence on Behavior
- Sleep and Wakefulness Research
- Prenatal Substance Exposure Effects
- Pain Management and Placebo Effect
- Cannabis and Cannabinoid Research
- Cardiomyopathy and Myosin Studies
- Maternal Mental Health During Pregnancy and Postpartum
- Sleep and related disorders
- Diet and metabolism studies
- Bipolar Disorder and Treatment
- Cardiovascular Function and Risk Factors
- Diabetes Treatment and Management
- Behavioral and Psychological Studies
- Neuropeptides and Animal Physiology
- Electroconvulsive Therapy Studies
- Hormonal Regulation and Hypertension
- RNA and protein synthesis mechanisms
- Pharmaceutical Practices and Patient Outcomes
- Hernia repair and management
- Gastrointestinal motility and disorders
Jazz Pharmaceuticals (United States)
2024
Alkermes (United States)
2018-2024
Alkermes (Ireland)
2017-2021
Dartmouth College
2013-2016
Dartmouth Psychiatric Research Center
2010
University of Miami
2007
Florida Atlantic University
2004-2005
Perinatal opioid use disorders negatively impact maternal and neonatal outcomes are a public health problem of increasing severity. More than half women with substance disorder have history posttraumatic stress that, if not adequately addressed, can impede treatment. This case report describes complexities in the treatment pregnant woman reviews psychotherapeutic pharmacologic approaches available to treat these co-occurring pregnancy. demonstrates importance early screening intervention for...
Injectable extended-release naltrexone (XR-NTX), approved to prevent relapse opioid dependence, requires initial abstinence. This multisite outpatient clinical trial examined the efficacy and safety of low-dose oral (NTX), combined with a brief buprenorphine (BUP) taper standing ancillary medications, for detoxification induction onto XR-NTX.Patients (N = 378) were randomized, stratified by primary short-acting opioid-of-use, one three regimens: NTX + BUP; placebo BUP (PBO-B); (PBO-N) PBO-B....
Weight gain and adverse cardiometabolic effects often limit the clinical utility of olanzapine. In ENLIGHTEN-2, combining olanzapine with opioid receptor antagonist samidorphan (OLZ/SAM) mitigated olanzapine-associated weight gain. These analyses tested hypothesis that OLZ/SAM would be associated reduced compared olanzapine.This phase 3 double-blind study randomized adults schizophrenia to or for 24 weeks. Post hoc assessed changes from baseline week in risk parameters, including body mass...
Abstract Background and Aims Extended‐release naltrexone (XR‐NTX), a μ‐opioid receptor antagonist for prevention of relapse to opioid dependence, has demonstrated efficacy compared with placebo comparative effectiveness buprenorphine–naloxone. We report outcomes XR‐NTX in Vivitrol's Cost Treatment Outcomes Registry. Design Observational, open‐label, single‐arm, multi‐center registry assessing baseline characteristics clinical health‐related quality‐of‐life associated treatment practice....
Abstract Background and aims Extended‐release formulations of naltrexone have emerged as effective treatment options for opioid use disorder. This post‐hoc analysis examined the temporal relationship between episodes subsequent dropout in a placebo‐controlled trial extended‐release injection (XR‐NTX) to draw inferences about mechanism by which extended blockade receptors translates into clinical effectiveness. Design was 24‐week multiple‐site, double‐blind, randomized monthly XR‐NTX versus...
Journal Article Expanding Cessation Pharmacotherapy Via Videoconference Educational Outreach to Prescribers Get access Mary F. Brunette, MD, MD 1Department of Psychiatry, Geisel School Medicine at Dartmouth, Lebanon, NH;2Department Health and Human Services, Bureau Behavioral Health, Concord, NH Search for other works by this author on: Oxford Academic PubMed Google Scholar Nino Dzebisashvili, PhD, PhD NH; Haiyi Xie, Sarah Akerman, Joelle C. Ferron, Stephen Bartels, Nicotine & Tobacco...
Patients with schizophrenia (SZ) or bipolar disorder (BD) may have increased risk of complications from prescribed opioids, including opioid-induced respiratory depression. We compared prescription opioid pain medication dispensing for patients SZ BD versus controls over 5 years to assess trends.
Dextromethorphan, a semi-synthetic morphine derivative, is widely available antitussive in many over-the-counter cough and cold preparations. When taken large amounts, it produces high effects similar to PCP. Emergency room poison control data suggest that abuse of this substance has increased the past decade. Adolescents, particularly those with co-occurring psychiatric use disorders, seem be at higher risk for dependence on dextromethorphan than children adults. Multiple case reports,...
Background and Objective When patients seek to discontinue buprenorphine (BUP) treatment, monthly injectable extended‐release naltrexone (XR‐NTX) may help them avoid relapse. The efficacy of low ascending doses oral NTX vs placebo for transitioning from BUP XR‐NTX is evaluated in this study. Methods In a phase 3, hybrid residential/outpatient study, clinically stable participants with opioid use disorder (N = 101), receiving more than or equal 3 months seeking antagonist were randomized...
After treatment with naltrexone extended-release injectable suspension (XR-NTX), a µ-opioid receptor antagonist, opioid tolerance is reduced from pretreatment baseline. Patients may be vulnerable to overdose if they attempt override the blockade during treatment, at end of dosing interval, after missing dose, or discontinuing treatment. We analyzed postmarketing data characterize reporting rates and discontinuation XR-NTX. Postmarketing adverse event reports within XR-NTX safety database,...
Opioid use disorder (OUD) is associated with cognitive dysfunction. Understanding how pharmacotherapy may affect cognition an important treatment consideration. This was a hybrid residential-outpatient, randomized trial assessing transition regimens (naltrexone/buprenorphine [NTX/BUP] vs placebo-NTX/buprenorphine [PBO-N]/BUP) to extended-release naltrexone (XR-NTX) in patients OUD seeking BUP discontinuation. Cognition assessed at baseline, Day 22 (XR-NTX 14), and 36 28) using range of...
Extended-release injectable naltrexone (XR-naltrexone) is effective for treatment of patients with opioid use disorder (OUD), but initiation remains a barrier due to the challenge tolerating withdrawal prior administration. Understanding factors associated successful XR-naltrexone could facilitate its implementation through patient-treatment matching.We combined data from five consecutive studies that sought initiate active onto using rapid procedure consisting minimal buprenorphine,...
Abstract Introduction Prior studies report high incidences of psychiatric and/or neurologic comorbidities in patients with narcolepsy. Low-sodium oxybate (LXB; Xywav®) is an FDA-approved treatment for cataplexy or excessive daytime sleepiness ≥7 years old narcolepsy and adults idiopathic hypersomnia. This post hoc analysis a phase 3 trial (NCT03030599) assessed LXB efficacy safety participants without medical history comorbidities. Methods Participants were (18‒70 years) cataplexy....